Connor, Clark & Lunn Investment Management (CC&L)
AIMT

Connor, Clark & Lunn Investment Management (CC&L)’s Aimmune Therapeutics AIMT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-23,814
Closed -$590K – 890
2017
Q3 		$590K Sell
23,814
-20,511
-46% -$442K ﹤0.01% 612
2017
Q2 		$911K Buy
44,325
+34,525
+352% +$659K 0.01% 514
2017
Q1 		$213K Buy
+9,800
New +$201K ﹤0.01% 792

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s AIMT Position: Q4 2017 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Aimmune Therapeutics (AIMT) in Q4 2017, closing a stake of 23,814 shares — an estimated $590K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AIMT in Q1 2017 and held it in 3 quarters. The position peaked at $911K in Q2 2017. 129 funds tracked by Wall St. Rank hold AIMT as of Q4 2017.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Aimmune Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 23,814 Aimmune Therapeutics shares in Q4 2017, an estimated $590K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Aimmune Therapeutics in Q1 2017 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Aimmune Therapeutics position peaked at $911K in Q2 2017.
  • 129 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2017.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2017, filed 9 Feb 2018.